Long-term follow-up of survival in Hodgkin's lymphoma

New England Journal of Medicine

Volumn 361, Issue 24, 2009, Pages 2390-2391

  Canellos, George P ^a   Niedzwiecki, Donna ^b   Johnson, Jeffrey L ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b Statistical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FOLLOW UP; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; LETTER; LONG TERM CARE; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT DURATION;

EID: 71849109593     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc0906731     Document Type: Letter

References (4)

1. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478-1484
2. Canellos GP, Niedzwiecki D. Long-term follow-up of Hodgkin's disease trial. N Engl J Med 2002;346:1417-1418 (Pubitemid 34754624)
3. Diehl V, Franklin J, Pfeundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348:2386-2395 [Erratum, N Engl J Med 2005;353:744.] (Pubitemid 36682817)
4. Brenner H, Gondos A, Pulte D. Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. Blood 2008;111:2977-2983